Skip Navigation


JAC Advance Access originally published online on March 16, 2007
Journal of Antimicrobial Chemotherapy 2007 59(5):886-892; doi:10.1093/jac/dkm072
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow An erratum has been published
Right arrow An erratum has been published
Right arrow All Versions of this Article:
59/5/886    most recent
dkm072v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kehrenberg, C.
Right arrow Articles by Schwarz, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kehrenberg, C.
Right arrow Articles by Schwarz, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2007. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Molecular mechanisms of decreased susceptibility to fluoroquinolones in avian Salmonella serovars and their mutants selected during the determination of mutant prevention concentrations

Corinna Kehrenberg1,*, Anno de Jong2, Sonja Friederichs2, Axel Cloeckaert3 and Stefan Schwarz1

1 Institut für Tierzucht, Bundesforschungsanstalt für Landwirtschaft (FAL), Höltystr. 10, 31535 Neustadt-Mariensee, Germany 2 Bayer HealthCare AG, Animal Health Division, Clinical Research & Development Antiinfectives, 40789 Monheim, Germany 3 Unité Infectiologie Animale et Santé Publique, Institut National de la Recherche Agronomique, 37380 Nouzilly, France

Received 7 December 2006; returned 26 January 2007; revised 12 February 2007; accepted 14 February 2007

* Corresponding author. Tel: +49-5034-871-242; Fax: +49-5034-871-246; E-mail: corinna.kehrenberg{at}fal.de

Objectives: Salmonella enterica isolates of six serovars and mutants obtained during determination of mutant prevention concentrations (MPCs) were investigated for mechanisms of decreased susceptibility to fluoroquinolones.

Methods: The quinolone resistance determining regions (QRDRs) of gyrA, gyrB, parC and parE genes were sequenced. MIC values were determined in the presence/absence of the efflux pump inhibitors carbonyl cyanide m-chlorophenyl-hydrazone (CCCP) or Phe-Arg-ß-naphthylamide (PAßN). PCR assays for the quinolone resistance genes qnrA, qnrB, qnrS or aac(6')-Ib-cr were applied. The MPC values of ciprofloxacin (MPCCIP) were determined for all isolates and selected mutants were investigated for their quinolone resistance mechanisms.

Results: In contrast to 11 nalidixic acid-susceptible isolates, 24 nalidixic acid-resistant isolates exhibited single mutations in gyrA (Asp-87 -> Tyr, Gly, Asn or Ser-83 -> Phe, Tyr) or parC (Thr-57 -> Ser). While CCCP had no influence on the MICs, PAßN decreased the MICCIP values by 1–3 dilution steps and MICNAL values by up to 6 dilution steps. Of the resistance genes investigated, only qnrS was present, in a single Salmonella Infantis isolate. The MPCCIP values were 4–64-fold higher than the MICs and ranged between 1–16 and 0.12–1 mg/L, respectively, for isolates resistant or susceptible to nalidixic acid. Only mutants obtained from formerly nalidixic acid-susceptible isolates developed single mutations in gyrA or gyrB.

Conclusions: In field isolates and mutants, target site mutations and efflux seem to be important mechanisms for decreased fluoroquinolone susceptibility. Mutants derived during MPC determination from field isolates already harbouring single-step mutations in gyrA did not exhibit further mutations in any target genes.

Keywords: ciprofloxacin , nalidixic acid , QRDR , efflux pump systems , qnr genes , fluoroquinolone modifying enzyme aac(6')-Ib-cr


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
C. Kehrenberg, A. Cloeckaert, G. Klein, and S. Schwarz
Decreased fluoroquinolone susceptibility in mutants of Salmonella serovars other than Typhimurium: detection of novel mutations involved in modulated expression of ramA and soxS
J. Antimicrob. Chemother., December 1, 2009; 64(6): 1175 - 1180.
[Abstract] [Full Text] [PDF]

Home page
 Appl. Environ. Microbiol.Home page
C. M. Jung, T. M. Heinze, J. Deck, R. Strakosha, and J. B. Sutherland
Transformation of N-Phenylpiperazine by Mixed Cultures from a Municipal Wastewater Treatment Plant
Appl. Envir. Microbiol., October 1, 2008; 74(19): 6147 - 6150.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
A. Cesaro, R. R. D. Bettoni, C. Lascols, A. Merens, C. J. Soussy, and E. Cambau
Low selection of topoisomerase mutants from strains of Escherichia coli harbouring plasmid-borne qnr genes
J. Antimicrob. Chemother., May 1, 2008; 61(5): 1007 - 1015.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
C. Kehrenberg, S. Friederichs, A. de Jong, and S. Schwarz
Novel Variant of the qnrB Gene, qnrB12, in Citrobacter werkmanii
Antimicrob. Agents Chemother., March 1, 2008; 52(3): 1206 - 1207.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.